Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
antimiR-208 (miR-208)
print preview
bookmark
share with colleague
General Information
Company
miRagen Therapeutics Inc.
Description
Modified short nucleic acid sequence targeting microRNA-208
Molecular Target
MicroRNA-208 (miR-208)
Mechanism of Action
Latest Stage of Development
Preclinical
Indication
Heart failure
Partner
Servier
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy